The regression of LVH with allopurinol therapy seen in
this study is consistent with a recently published human
study showing that allopurinol regresses LVM in chronic
kidney disease (11). It is also consistent with 3 experimental
animal studies showing that xanthine oxidase inhibitors can
regress LVH (8–10). Our secondary findings are consistent
with a recently published study showing allopurinol to
improve FMD and AIx in very similar patients